Tyra Biosciences Inc (TYRA)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$19.04

+0.34 (+1.82%)

Market Cap: $1.28B

Last updated: Oct 16, 2026 at 1:55 PM ET

Earnings

Performance (10Y)

Beat Rate

50%(10/20)

Avg Surprise

-3.92%

Upcoming Estimates

Period ending Sep 30, 2026

EPS Consensus$-0.67

Range$-0.76 - $-0.47

14 analysts

EPS Revisions

30d

EPS Estimate DriftChange to current

90d ago$-0.65-2.7%

60d ago$-0.65-3.0%

30d ago$-0.68+2.7%

7d ago$-0.67+0.4%

Current$-0.67

Revenue Consensus

Range$0 - $0

12 analysts

Period ending Dec 31, 2026

EPS Consensus$-0.74

Range$-0.95 - $-0.30

14 analysts

Revenue Consensus

Range$0 - $0

12 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-0.74	$-0.95 - $-0.30	-	-	14	-	-
Sep 30, 2026Sep 26EST	-	$-0.67	$-0.76 - $-0.47	-	-	14	2 0 30d	-
Jun 30, 2026Jun 26 Reported Aug 4, 2026Reported Aug 4	$-0.69	$-0.67	$-0.70 - $-0.56	-2.99%	Miss	14	1 0 30d	-46.8%
Mar 31, 2026Mar 26 Reported May 13, 2026Reported May 13	$-0.64	$-0.58	$-0.64 - $-0.56	-10.34%	Miss	10	1 4 30d	-36.2%
Dec 31, 2025Dec 25 Reported Mar 2, 2026Reported Mar 2	$-0.57	$-0.53	$-0.63 - $-0.46	-7.55%	Miss	9	1 0 30d	-32.6%
Sep 30, 2025Sep 25 Reported Nov 5, 2025Reported Nov 5	$-0.50	$-0.50	$-0.60 - $-0.47	+0.00%	Beat	5	2 0 30d	-22.0%
Jun 30, 2025Jun 25 Reported Aug 14, 2025Reported Aug 14	$-0.47	$-0.51	$-0.58 - $-0.46	+7.84%	Beat	5	1 2 30d	-46.9%
Mar 31, 2025Mar 25 Reported May 8, 2025Reported May 8	$-0.47	$-0.48	$-0.56 - $-0.41	+2.08%	Beat	4	0 1 30d	-34.3%
Dec 31, 2024Dec 24 Reported Mar 27, 2025Reported Mar 27	$-0.43	$-0.48	$-0.56 - $-0.37	+10.42%	Beat	6	1 4 30d	+18.9%
Sep 30, 2024Sep 24 Reported Nov 7, 2024Reported Nov 7	$-0.41	$-0.39	$-0.45 - $-0.35	-5.13%	Miss	7	No revisions (30d)	+16.3%
Jun 30, 2024Jun 24 Reported Aug 7, 2024Reported Aug 7	$-0.32	$-0.39	$-0.46 - $-0.36	+17.95%	Beat	6	No revisions (30d)	-3.2%
Mar 31, 2024Mar 24 Reported May 9, 2024Reported May 9	$-0.35	$-0.46	$-0.53 - $-0.42	+23.91%	Beat	6	No revisions (30d)	-25.0%
Dec 31, 2023Dec 23 Reported Mar 19, 2024Reported Mar 19	$-0.53	$-0.48	$-0.55 - $-0.43	-10.42%	Miss	6	No revisions (30d)	-71.0%
Sep 30, 2023Sep 23 Reported Nov 7, 2023Reported Nov 7	$-0.49	$-0.35	$-0.40 - $-0.31	-40.00%	Miss	6	No revisions (30d)	-63.3%
Jun 30, 2023Jun 23 Reported Aug 10, 2023Reported Aug 10	$-0.31	$-0.34	$-0.42 - $-0.29	+8.82%	Beat	6	No revisions (30d)	+13.9%
Mar 31, 2023Mar 23 Reported May 4, 2023Reported May 4	$-0.28	$-0.37	$-0.43 - $-0.28	+24.32%	Beat	5	1 0 30d	+22.2%
Dec 31, 2022Dec 22 Reported Mar 22, 2023Reported Mar 22	$-0.31	$-0.36	$-0.40 - $-0.34	+13.89%	Beat	5	No revisions (30d)	-29.2%
Sep 30, 2022Sep 22 Reported Nov 3, 2022Reported Nov 3	$-0.30	$-0.39	$-0.45 - $-0.37	+23.08%	Beat	4	No revisions (30d)	+58.3%
Jun 30, 2022Jun 22 Reported Aug 4, 2022Reported Aug 4	$-0.36	$-0.30	$-0.30 - $-0.30	-20.00%	Miss	0	No revisions (30d)	-50.0%
Mar 31, 2022Mar 22 Reported May 5, 2022Reported May 5	$-0.36	$-0.20	$-0.20 - $-0.20	-80.00%	Miss	2	No revisions (30d)	-800.0%
Dec 31, 2021Dec 21 Reported Mar 3, 2022Reported Mar 3	$-0.24	$-0.21	$-0.24 - $-0.19	-14.29%	Miss	3	No revisions (30d)	+88.5%
Sep 30, 2021Sep 21 Reported Nov 3, 2021Reported Nov 3	$-0.72	$-0.60	$-0.69 - $-0.51	-20.00%	Miss	2	No revisions (30d)	+60.1%
Jun 30, 2021Jun 21 Reported Sep 15, 2021Reported Sep 15	$-0.24	$0.00	-	N/A	Miss	-	-	+86.7%
Mar 31, 2021Mar 21 Reported May 28, 2021Reported May 28	$-0.04	$0.00	-	N/A	Miss	-	-	+96.8%
Dec 31, 2020Dec 20 Reported Mar 31, 2021Reported Mar 31	$-2.09	$0.00	-	N/A	Miss	-	-	-96.3%
Sep 30, 2020Sep 20 Reported Dec 31, 2020Reported Dec 31	$-1.80	$0.00	-	N/A	Miss	-	-	-
Jun 30, 2020Jun 20 Reported Sep 30, 2020Reported Sep 30	$-1.80	$0.00	-	N/A	Miss	-	-	-
Mar 31, 2020Mar 20 Reported Jun 29, 2020Reported Jun 29	$-1.27	$0.00	-	N/A	Miss	-	-	-
Dec 31, 2019Dec 19 Reported Mar 30, 2020Reported Mar 30	$-1.07	$0.00	-	N/A	Miss	-	-	-

Key Metrics

Valuation
P/E Ratio	-7.93	EV/EBITDA	N/A
Price/FCF	-11.43x	FCF Yield	-8.75%
Profitability
Profit Margin	0.00%	Operating Margin	0.00%
ROE	-45.30%	ROIC	N/A
Financial Health
Debt/Equity	0.00x	Interest Coverage	N/A
Current Ratio	14.91x	Quick Ratio	14.91x
Trading Statistics
Beta	0.75	Avg Volume	856.44K
52-Week High	$40.65	52-Week Low	$13.35

Technical Indicators Dashboard

Moving Averages

SMA 10$19.78

SMA 20$21.42

SMA 50$23.85

SMA 200$30.28

EMA 10$19.84

EMA 20$21.06

EMA 50$23.72

EMA 200$26.39

MACD

Line: -1.60Signal: -1.48Hist: -0.11

ADX

ADX: 23.4+DI: 18.0-DI: 32.5

Aroon & PSAR

Aroon Up28.0

Aroon Down96.0

PSAR$24.69

Bollinger Bands

Upper Band$25.81

Lower Band$17.04

%B Position4092%(Upper)

Band Width0.23

RSI (14-Day)

Neutral

33.8

Momentum Oscillators

Stoch %K9.6

Stoch %D5.6

Williams %R-81.9

ROC (10d)-9.4%

Momentum-1.97

CCI (20d)-95.9

MFI (14d)33.7

Volatility Measures

ATR (14d)$1.27(6.7%)

StdDev (20d)2.19

Hist Vol50.6%(High)

Volume Flow

VWAP$19.03

OBV10.3M

AD Line15.3M

CMF (20d)-0.214

Volume Metrics

Avg Vol (20d)859.6K

Vol Ratio0.5x(Low)

VWMA (20d)$22.18

Pivot Points

R3$19.51

R2$19.17

R1$18.93

Pivot Point$18.59

S1$18.36

S2$18.02

S3$17.78

Advanced Oscillators

TSI-29.10

Ultimate Osc39.9

KST-193.38

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$0	$0	$0	$0	$0	$0	$496,000	$0	$0	$0	$502,000	$0
Cost of Revenue	$0	$0	$132,000	$0	$0	$0	N/A	$0	$0	$0	$102,000	$0
Gross Profit	$0	$0	$-132,000	$0	$0	$0	$248,000	$0	$0	$0	$400,000	$0

Operating Expenses	$49.00M	$42.00M	$36.52M	$32.94M	$31.45M	$31.85M	$29.72M	$28.60M	$23.53M	$22.32M	$25.63M	$23.96M
R&D	$39.20M	$33.47M	$28.19M	$25.47M	$24.31M	$24.96M	$22.18M	$22.70M	$18.00M	$17.20M	$20.68M	$19.27M
SG&A	$9.81M	$8.53M	$8.33M	$7.47M	$7.14M	$6.89M	$7.54M	$5.91M	$5.54M	$5.12M	$4.96M	$4.69M
Operating Income	$-49,003,000	$-41,998,000	$-36,516,000	$-32,944,000	$-31,452,000	$-31,850,000	$-29,719,000	$-28,604,000	$-23,532,000	$-22,322,000	$-25,634,000	$-23,963,000

Interest Income	$3.44M	$2.69M	$2.68M	$3.08M	$3.35M	$3.70M	$4.15M	$4.59M	$4.83M	$4.13M	$2.80M	$2.81M
Interest Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Income Before Tax	$-45,558,000	$-39,305,000	$-33,834,000	$-29,868,000	$-28,098,000	$-28,147,000	$-25,571,000	$-24,016,000	$-18,702,000	$-18,192,000	$-22,830,000	$-21,152,000
Income Tax Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0

Net Income	$-45,558,000	$-39,305,000	$-33,834,000	$-29,868,000	$-28,098,000	$-28,147,000	$-25,571,000	$-24,016,000	$-18,702,000	$-18,192,000	$-22,830,000	$-21,152,000

EBITDA	$-48,865,000	$-41,860,000	$-36,384,000	$-32,813,000	$-31,312,000	$-31,707,000	$-29,575,000	$-28,477,000	$-23,406,000	$-22,200,000	$-25,532,000	$-23,880,000
EBIT	$-49,003,000	$-41,998,000	$-36,516,000	$-32,944,000	$-31,452,000	$-31,850,000	$-29,719,000	$-28,604,000	$-23,532,000	$-22,322,000	$-25,634,000	$-23,963,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about TYRA

News

Avoiding Lag: Real-Time Signals in (TYRA) Movement

This article analyzes Tyra Biosciences Inc. (NASDAQ: TYRA), highlighting weak near and mid-term sentiment but a positive long-term outlook. It provides AI-generated trading strategies for different risk profiles...

Stock Traders Daily•Oct 14, 2026 11:48 AM ET10/14/26•Somewhat-Bearish

Here's Why Tyra Biosciences (TYRA) is Poised for a Turnaround After Losing 27% in 4 Weeks

Tyra Biosciences (TYRA) has experienced a 27% stock price drop in the last four weeks, but indicators suggest a potential turnaround. The stock is currently in oversold territory according to its Relative Strength Index...

Yahoo! Finance Canada•Oct 14, 2026 4:35 AM ET10/14/26•Bullish

Law firm probes Tyra Biosciences over possible securities fraud after drug trial safety concerns.

Pomerantz LLP is investigating Tyra Biosciences and its executives for potential securities fraud following drug trial results for dabogratinib. Despite a favorable safety profile...

Pluang•Oct 13, 2026 6:14 PM ET10/13/26•Bearish

Tyra Biosciences, Inc. Rings the Nasdaq Stock Market Opening Bell

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company specializing in precision medicines for FGFR biology, rang the Nasdaq Stock Market Opening Bell. Todd Harris, CEO...

Nasdaq•Oct 13, 2026 9:14 AM ET10/13/26•Bullish

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Tyra Biosciences, Inc. (TYRA) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential claims against Tyra Biosciences...

ACCESS Newswire•Oct 11, 2026 6:41 AM ET10/11/26•Bearish

TYRA Valuation and Fair Value

P/E: -7.9x
P/FCF: -11.4x
P/B: 3.6x

See GNG's fair value

TYRA Profitability: Margins, ROIC and FCF

Operating margin: 0.0%
Net margin: 0.0%
ROE: -45.3%
FCF yield: -8.7%

TYRA Competitors

Company	Ticker
Alpha Tau Medical Ltd	DRTS
U.S. Physical Therapy, Inc.	USPH
Mind Medicine Inc	MNMD
Nektar Therapeutics	NKTR
Omeros Corporation	OMER
Inhibrx Biosciences, Inc.	INBX
CONMED Corporation	CNMD
Syndax Pharmaceuticals Inc	SNDX

Sector: Healthcare

TYRA Analyst Ratings

Consensus: Buy
Analysts: 15
Strong Buy: 2
Buy: 12
Hold: 1
Sell: 0
Strong Sell: 0

TYRA Bull Case vs Bear Case

Bull case

93.3% of TYRA's analyst ratings are Buy or Strong Buy.

Bear case

TYRA beat EPS estimates in 37.5% of its last 8 reported quarters.

TYRA Earnings: Beat Rate and Next Report

Beat rate: 3 of 8 quarters (37.5%)
Average surprise: -0.7%
EPS estimate (fiscal period ending Sep 30, 2026): $-0.67
Estimate revisions (30 days, fiscal period ending Sep 30, 2026): 2 up, 0 down

Frequently Asked Questions About TYRA

Does TYRA pay dividends?

Tyra Biosciences Inc (TYRA) does not currently pay a regular dividend.

What is TYRA's market cap?

Tyra Biosciences Inc (TYRA) has a market capitalization of $1.28B with a current stock price of $19.04.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In